Joseph G. Reynolds

TL;DR: Preclinical and Phase 1 data suggest that MM-302, as a monotherapy or in combination with trastuzumab, could be effective for managing previously treated, anthracycline-naïve, HER2-positive breast cancer, without the cardiotoxicity observed with free doxorubicin formulations.

TL;DR: Her2-targeted liposomal doxorubicin is demonstrated to have little or no uptake into human cardiomyocytes, does not inhibit HER2-mediated signaling, and retains the low penetration into heart tissue of liposomes of anthracyclines.

TL;DR: MM-302 monotherapy, in combination with trastuzumab, or trastizumab plus cyclophosphamide, was well tolerated and showed promising efficacy in HER2-positive locally advanced/metastatic breast cancer.

TL;DR: It is reported that dystrophic muscle exhibits reduced PKA activity resulting, in part, from severely mislocalized myospryn and the type II regulatory subunit (RIIα) of PKA and it is shown that myosp Kathryn and dystrophin coimmunoprecipitate in native muscle extracts and directly interact in vitro.

TL;DR: It is demonstrated that myospryn co-localizes with RII alpha, a type II regulatory subunit of PKA, at the peripheral Z-disc/costameric region in striated muscle, which point to localized PKA signaling at the muscle costamere.